Results 241 to 250 of about 28,483 (297)

Efficacy and Safety of Various Intravenous Thrombolytics for Acute Ischemic Stroke (AIS) at Various Dosages: A Systematic Review and Network Meta-Analysis. [PDF]

Neurol Ther
Hu Y, Wu S, Zhang H, Wang K, Zhang L, Ma Y, Li H.   +6 more
europepmc   +1 more source

Efficacy and safety of intra-arterial thrombolysis after endovascular reperfusion for acute ischemic stroke: a systematic review and meta-analysis of randomized trials. [PDF]

Int J Surg
Guo Y, Yang G, Ding Y, Liu C, Shen Z, Zhang H, Bao Q, Luo W.   +7 more
europepmc   +1 more source

Sphingosine-1-Phosphate Modulation in Neurological Disorders: Insights from MS and Stroke. [PDF]

Brain Sci
Maktabi B, Shehjar F, Senger Z, Kountz L, Hasan S, Maaieh K, Hoersten K, Duric J, Shah ZA.   +8 more
europepmc   +1 more source

Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): update to study protocol and addition of a statistical analysis plan and health economic analysis plan for a randomised controlled surgical trial. [PDF]

Trials
Lee CN, Desai R, Ramazzotto L, Wafa H, Wang Y, Bunce C, Doungsong K, Ezeofor V, Edwards RT, Lois N, Steel DH, Peto T, Hillenkamp J, van Meurs JC, Reeves BC, Jackson TL.   +15 more
europepmc   +1 more source

Treatment outcomes in pediatric empyema: a retrospective observational study from a tertiary center in Dubai, United Arab Emirates. [PDF]

Pediatr Surg Int
Al Blooshi M, Ahmad M, Al Shamali F, Uddin W, Jaber G, Al Marzouqi M, Hiremath A, Kader MA, Gupta V.   +8 more
europepmc   +1 more source

Combination Dornase and Alteplase for Intra-abdominal Drain, Abscess, and Hematoma Clearance: A Retrospective Case Series. [PDF]

J Pharm Technol
Schultz M, Patel J, Olsen M, Nordbeck S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Alteplase for acute ischemic stroke

Expert Review of Cardiovascular Therapy, 2006
Alteplase, an intravenously administered form of recombinant tissue plasminogen activator (rt-PA), remains the only US FDA-approved thrombolytic treatment for acute ischemic stroke within 3 h of symptom onset. Patients treated with intravenous rt-PA are at least 30% more likely to have minimal or no disability at 3 months compared with placebo. Despite
Nicole R. Gonzales, James C. Grotta
openaire   +2 more sources

Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial

Stroke, 2023
BACKGROUND: Reteplase is a more affordable new-generation thrombolytic with a prolonged half-life. We aimed to determine the safety dose range of reteplase for patients with acute ischemic stroke within 4.5 hours of onset. METHODS: This is a multicenter,
Shuya Li, Xuechun Wang, A. Jin, Gaifen Liu, H. Gu, Hao Li, B. Campbell, Marc Fisher, Yi Yang, Yan Wei, Junhai Wang, Yilong Wang, Xing-hui Zhao, Liping Liu, Zixiao Li, Xia Meng, Yongjun Wang   +16 more
semanticscholar   +1 more source

Stability of alteplase in presence of cavitation

Ultrasonics, 2008
Several experimental studies have demonstrated that ultrasound (US) can accelerate enzymatic fibrinolysis and this effect is further enhanced in the presence of ultrasound contrast agents (UCA). Although UCA have been shown to be safe when administered to ischemic stroke patients, safety information of these agents in the thrombolysis setting is ...
Adrian F. Prokop, Azita Soltani, Sara Vaezy   +2 more
openaire   +3 more sources